Biotechnology
Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST
Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments
Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.
Read
Commented by André Will-Laudien on July 11th, 2024 | 06:45 CEST
Mega rally on the cards - 500% plus is likely too low an estimate! Evotec, Desert Gold, Cogia, VCI Global, and Lufthansa
The stock market keeps rising and rising - this much is revealed by the ever-new highs of prominent indices such as the NASDAQ 100, S&P 500, or the Nikkei index. However, a closer look reveals some inconsistencies. For example, only 6% of all traded stocks are currently reaching new highs, while over 70% of all listed stocks have fallen since the beginning of the year. In short, global liquidity is aggregated in just a few blockbuster stocks, with the rest being left behind. Such bubbles already occurred in 1999, 2007, and 2015, followed by a 25% to 50% correction. When exactly this will happen, no one knows, but the party is likely to continue for a while due to high liquidity. Gold and silver are in the process of forming interesting breakout formations. Now is the time to pick the cherries!
Read
Commented by Armin Schulz on July 9th, 2024 | 07:07 CEST
Varta, Cardiol Therapeutics, Evotec - ATTENTION: Something is happening here!
The stock markets are currently seeing increased activity in Varta, Cardiol Therapeutics, and Evotec. Investors should take advantage of the resulting opportunities. Increased volatility and trading volumes can offer attractive short-term gains, while improved liquidity facilitates entry and exit. Additional information flows and momentum effects enhance the dynamics of these stocks, although they also carry increased risks. Sound analysis and prudent risk management are, therefore, essential. We take a closer look at what is currently happening with these three stocks.
Read
Commented by Juliane Zielonka on July 5th, 2024 | 07:35 CEST
Vidac Pharma, BioNTech, GSK: Pioneers in medical progress - Who will win the race?
With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time, a patent dispute is raging between Moderna and BioNTech, which could significantly impact the future of mRNA technology. This makes the strategic partnership between GSK and CureVac all the more important. The British company GSK is paying billions of euros for rights to COVID-19 and flu vaccines, which CureVac is to develop. During the pandemic, CureVac was noted more for its shortcomings in vaccine development. Will they achieve a breakthrough now?
Read
Commented by André Will-Laudien on July 1st, 2024 | 07:00 CEST
Attention: Biotech stocks! Evotec, Bayer, and BioNTech in the emergency room, but Cardiol Therapeutics shows strength!
Anyone looking at the buying frenzy on the NASDAQ is overlooking the fact that the US has long been in the emergency room. With the candidates currently up for election, it is unlikely that the most pressing issues of the day will be dealt with. One has difficulty using the right words in front of the camera, while the other ignores facts and slips into his own world. This election could be disastrous for the world's largest economy, but the financial markets are currently uninterested. Investors should, therefore, continue to separate the wheat from the chaff and act prudently. After the big AI and high-tech wave, biotechs are expected to make a comeback, as US interest rates will drop closer to the election. We present a solid selection for risk-conscious investors.
Read
Commented by Armin Schulz on June 25th, 2024 | 08:45 CEST
Evotec, Royal Helium, Nel ASA - Turnaround candidates under review
With the recent rise in shares in Power Nickel, following a bonanza find in its exploration work, the topic of "turnaround candidates on the stock market" is once again coming to the fore. Such companies, which get back on track after significant price falls, offer investors enormous profit potential. The recovery after a deep crisis can represent a second chance for investors but requires a keen sense of market analysis and timing. The success of the investment depends largely on the right selection and timing of entry. We take a look at three candidates.
Read
Commented by Fabian Lorenz on June 25th, 2024 | 07:00 CEST
300%-Opportunity, problems, and the German Chancellor: Bayer, BioNTech, and Cardiol Therapeutics
Bayer is making positive headlines for a change. Following takeovers in cell and gene therapy, the Company is investing in Berlin and has brought the renowned Charité Hospital on board. Federal Chancellor Olaf Scholz gives the go-ahead for the project. Can the share benefit from this? The sell-off in Cardiol Therapeutics shares after positive study results was a surprise. Analysts are enthusiastic, raising price targets and seeing 300% potential. On the other hand, BioNTech shares are currently not an obvious buy. And now there are also problems with the FDA in the US. This is causing alarm among shareholders and impacting the share.
Read
Commented by Stefan Feulner on June 24th, 2024 | 11:15 CEST
Plug Power, Carbon Done Right, Evotec - Turnaround after the price slump
After the price surges in recent weeks, there were initial signs of a temporary top formation in the major US indices, including the Dow Jones, S&P 500, and the tech-heavy Nasdaq. It is hardly surprising, given that these indices have been in overbought territory since the upward trend that began in November. Once again, it is crucial for investors to pick the winners of the coming weeks despite a possible correction.
Read
Commented by André Will-Laudien on June 21st, 2024 | 07:00 CEST
Biotech: What counts is selection! Bayer, Vidac Pharma, Formycon, and Evotec in focus
The biotech sector has so far been unable to keep pace with the high-tech-heavy NASDAQ. However, there are now signals from the central banks that a turnaround in interest rates is imminent. This is because, on the one hand, the US economy is weakening, and on the other hand, inflationary pressure appears to be easing. With lower interest rates, life science companies can refinance themselves more cheaply. Due to the different dynamics, it is now important to fish out the pearls. We select attractive entry levels.
Read
Commented by Armin Schulz on June 17th, 2024 | 06:30 CEST
BioNTech, dynaCERT, Plug Power - A single piece of news can change everything
Share prices are characterized by their high volatility and can undergo significant changes in a short space of time. Often, just one piece of company news can completely change investor confidence. Shares that were previously under selling pressure and were avoided can suddenly become very popular and experience considerable price increases. Examples include Lufthansa, whose share price rose significantly with the end of the COVID-19 pandemic. Market sentiment can turn quickly when negative factors disappear. A single piece of positive company news can prompt investors to become more involved again, significantly increasing demand and, consequently, the share price. We have identified three potential turnaround candidates.
Read